That's Interesting
That's interesting archive
In this Goodfellow podcast episode, endocrinologist Ryan Paul discusses sick day management in patients with diabetes.
This article explores the inequities experienced by Pacific peoples with gout and outlines a novel innovative intervention strategy to improve the uptake of urate-lowering therapy in this population.
International Journal for Equity in Health.
In this article from New Zealand Doctor Rata Aotearoa, Dr Lucy O'Hagen explores her own pro-equity care and the challenges that patients face.
This report from Pharmac explores the data around Pacific peoples with gout. This report was developed to support people in the decisions they make to improve the management of gout, and enhance the well-being of Pacific peoples.
This open access article explores cardiovascular risk in Aotearoa and highlights how continued focus on preventing and managing CVD, especially from the perspective of those experiencing inequities is needed.
New Zealand Medical Journal
Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that reduces low-density lipoprotein cholesterol (LDL-C) levels. From 1 December 2021, it became fully funded for the management of cardiovascular disease and familial hypercholesterolaemia for patients meeting Special Authority criteria.
This Medcase describes the safe prescribing of rosuvastatin for the prevention of cardiovascular disease.
Pharmac has made a decision around the supply of perindopril tablets.
This decision means that:
- There will be no change for people currently on perindopril treatment.
- Coversyl will remain the funded brand of perindopril tablets.
- The price of perindopril 2mg and 4mg tablets will change from 1 January 2022.
- A higher strength 8mg tablet will be funded in the future, subject to Medsafe approval.
The addition of the 8mg option will provide a similar opportunity for effective treatment with one tablet once a day, as previously possible with cilazapril.
Pharmac has today released the first of a series of reports investigating inequities in medicine access. The report looks specifically at prescribing and dispensing medicines for gout, estimating 10,400 more Māori need preventive treatment each year to achieve equity in access to these medicines.
Māori leadership is standing out strongly in students emerging in the healthcare sector who are united in one goal, improving Māori healthcare outcomes.
Group Chief Executive Josephine Gagan from New Zealand Health Group said they were very impressed by the high calibre of the 172 applications they received for their Māori Health Leadership Scholarship programme. The $20,000 scholarship awarded annually is one of New Zealand Health Group’s initiatives in building equity in health and wellness in Aotearoa New Zealand, and enables more Māori to be in decision-making leadership roles within the health sector.
Click the link above to read the full press release.
Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab (Amgevita), improving access to adalimumab for more than 700 New Zealanders.
Adalimumab is used to treat a range of rheumatology, gastrointestinal, dermatological, and other autoimmune conditions. Around 6,400 kiwis have this injection, often fortnightly.
You can read the full Pharmac media release, and find helpful resources on this page.